RBC Capital on Aardvark Therapeutics Inc (AARD): 'We See Substantial Upside Potential On Positive Data'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $21.00 price target on Aardvark Therapeutics Inc (NASDAQ: AARD).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
